An FDA advisory panel has recommended approval for specific peptide-based treatments, sparking debate over their safety and effectiveness. These compounds are widely marketed for benefits like muscle development, weight management, and slowing aging, yet scientific evidence supporting these claims remains limited. Critics emphasize that long-term side effects are poorly understood and that regulatory scrutiny has not kept pace with the growing demand in the wellness sector.
The panel’s endorsement may lead to wider access to these treatments, but it also raises concerns about misleading advertising and improper use. Experts caution that without strong oversight, consumers could be exposed to unproven therapies. NBC News’ Anne Thompson breaks down the science, the panel’s reasoning, and the broader impact on public health. As the FDA reviews the recommendation, the decision underscores the ongoing challenge of balancing medical innovation with consumer safety in an evolving industry.